Skip to content

SRTA SRTA Impairment of long-lived assets

Impairment of long-lived assets at other companies

Alto Ingredients, Inc. logo
Alto Ingredients, Inc.ALTO
$200.75K-96.8%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0
UBS
United BanksharesUBSI
$13.75K-74.9%
APO
Apogee EnterprisesAPOG
$4.06M-46.8%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$0-100%
Encore Capital Group logo
Encore Capital GroupECPG
$0-100%

Other financials

Income statement

See full
Revenue$67.4M+87.4%
Gross profit$14.1M+100%
Operating income-$3.0M+47.7%
Net income$2.2M+162%
EPS (diluted)$0.03+175%

Balance sheet

See full
Cash & equivalents$59.0M+65.3%
Total debt$4.5M-50.7%
Total equity$285.7M+30.0%
Total assets$327.6M+30.8%

Cash flow

See full
Operating cash flow$3.9M+1,679%
CapEx$5.2M+98.1%
Free cash flow-$1.3M+54.8%

Valuation

See full
Market cap$463.78M+24.0%
Enterprise value$409.26M
P/E8.9×
P/S1.8×

Profitability

See full
Gross margin21.7%+1.3pp
Operating margin-7.8%-2.8pp
Net margin21%+13.6pp
FCF margin-22.4%+1,712pp

Returns & leverage

See full
Return on equity15.6%+10.0pp
Debt / equity0.0×
Current ratio5.9×-1.0×

Where this comes from

Reported directly by SRTA in its filing.

Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.

The official record: SRTA’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about SRTA's impairment of long-lived assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SRTA's impairment of long-lived assets?
SRTA (SRTA) reported impairment of long-lived assets of $418.25K in Q4 2025.
What does impairment of long-lived assets mean?
This metric quantifies the non-cash charge recognized when the carrying amount of a long-lived tangible asset exceeds its recoverable amount. It indicates that the asset's value has declined due to obsolescence, physical damage, or changes in market conditions. High impairment charges often signal a need to re-evaluate the productivity or strategic value of the company's asset base.